Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From May 2019 to May 2024
TKT Announces Appointment of Eric Pauwels as Senior Vice
President, Global Commercial Operations
CAMBRIDGE, Mass., March 29 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) today announced that Eric Pauwels will join the company as
Senior Vice President, Global Commercial Operations effective April 13, 2005.
In this position, Mr. Pauwels will have overall responsibility for TKT's
worldwide commercialization initiatives, including the potential launch of
iduronate-2-sulfatase (I2S) for Hunter syndrome and ongoing marketing efforts
for Replagal(TM), TKT's enzyme replacement therapy for Fabry disease. In
addition, Mr. Pauwels will provide commercial input on the prioritization and
value of TKT's emerging new product pipeline.
"Eric joins TKT at an exciting time as we prepare to expand our marketing and
sales efforts and introduce new products to the marketplace," said David D.
Pendergast, Ph.D., Executive Vice President and Chief Operating Officer of TKT.
"With nearly twenty years of commercial pharmaceutical experience, Eric has
successfully led marketing and sales activities in the United States, Europe
and Asia. Eric will play a significant role in expanding TKT's commercial
expertise and will provide strong direction to TKT as we execute on new
initiatives, including our anticipated first commercial U.S. launch in 2006."
Mr. Pauwels joins TKT from Bayer Healthcare Pharmaceuticals where he most
recently managed the global commercialization for LEVITRA(R) for erectile
dysfunction in his role as Vice President Global Strategic Marketing, Men's
Health. Previously, he was Vice President Global Strategic Marketing,
Cardiovascular at Bayer and held several positions of increasing responsibility
in sales and marketing at Laboratories Fournier for more than four years. Mr.
Pauwels has also held marketing and sales positions at Janssen Pharmaceutica
Products and McNeil Pharmaceuticals where he managed several product launches,
including RISPERDAL(R) for psychotic disorders. He received a B.Sc. from
California State Polytechnic University, Pomona.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused
on researching, developing and commercializing treatments for rare diseases
caused by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com/.
This press release contains forward-looking statements regarding TKT's
management structure, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should," "could,"
"will," "may," and similar expressions. There are a number of important
factors that could cause the company's actual results to differ materially from
those indicated by such forward-looking statements, including whether TKT will
successfully manage its marketing and sales operations; the impact of competing
products on Replagal; whether the FDA and equivalent regulatory authorities
will approve I2S on a timely basis, or at all; and other factors set forth
under the caption "Certain Factors That May Affect Future Results" in the
company's Annual Report on Form 10-K for the year ended December 31, 2004,
which is on file with the Securities and Exchange Commission and are
incorporated herein by reference. While the company may elect to update
forward-looking statements at some point in the future, the company
specifically disclaims any obligation to do so, even if its expectations
change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
LEVITRA(R) is a registered trademark of Bayer Healthcare Pharmaceuticals and
RISPERDAL(R) is a registered trademark of Janssen Pharmaceutica Products, L.P.
For More Information Contact:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 349-0271
Daniella M. Lutz
Manager, Corporate Communications
(617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/
DATASOURCE: Transkaryotic Therapies, Inc.
CONTACT: Justine E. Koenigsberg, Senior Director, Corporate
Communications, +1-617-349-0271, or Daniella M. Lutz, Manager, Corporate
Communications, +1-617-349-0205, both of Transkaryotic Therapies, Inc.
Web site: http://www.tktx.com/
Company News On-Call: http://www.prnewswire.com/comp/120657.html